

44. Jeffrey Balch, Chicago, Illinois, Court of Federal Claims No: 20–0872V
45. Elaine Montana, Boston, Massachusetts, Court of Federal Claims No: 20–0873V
46. Susan Greenberg-Folkman, Los Ranchos, New Mexico, Court of Federal Claims No: 20–0874V
47. Wanda Oliver, Boston, Massachusetts, Court of Federal Claims No: 20–0877V
48. Jerry L. Bailey, Moline, Illinois, Court of Federal Claims No: 20–0878V
49. Jasmine Dede, Elmont, New York, Court of Federal Claims No: 20–0880V
50. Domenica Foster, Medford, New Jersey, Court of Federal Claims No: 20–0882V
51. Eric Simmons, Boston, Massachusetts, Court of Federal Claims No: 20–0884V
52. Gesdia Kelly, Phoenix, Arizona, Court of Federal Claims No: 20–0885V
53. Mark Thomas on behalf of Z. T., Loxahatchee, Florida, Court of Federal Claims No: 20–0886V
54. John Timothy Hamilton, Boston, Massachusetts, Court of Federal Claims No: 20–0887V
55. Thomas Bierbaum, Edina, Minnesota, Court of Federal Claims No: 20–0888V
56. Shaun Gladders, New Lenox, Illinois, Court of Federal Claims No: 20–0891V
57. Kyle Bolick, Omaha, Nebraska, Court of Federal Claims No: 20–0893V
58. Brandon Robison, Yakima, Washington, Court of Federal Claims No: 20–0896V
59. Christopher Diane Lewis, Dallas, Texas, Court of Federal Claims No: 20–0898V
60. Jan Koonce, Boston, Massachusetts, Court of Federal Claims No: 20–0899V
61. Paula Doze, Boston, Massachusetts, Court of Federal Claims No: 20–0900V
62. Raymond Balcer, Boston, Massachusetts, Court of Federal Claims No: 20–0901V
63. James Harkins, Hamilton, Montana, Court of Federal Claims No: 20–0902V
64. Sapna Patel, Houston, Texas, Court of Federal Claims No: 20–0903V
65. Russell Ramsey, Oklahoma City, Oklahoma, Court of Federal Claims No: 20–0904V
66. Allison Romansky, Baltimore, Maryland, Court of Federal Claims No: 20–0907V
67. Constance Nichols, Watertown, New York, Court of Federal Claims No: 20–0912V
68. Georgina Ransford, Washington, District of Columbia, Court of Federal Claims No: 20–0914V
69. Jason Barrow, Washington, District of Columbia, Court of Federal Claims No: 20–0915V
70. Christopher Dougherty, Washington, District of Columbia, Court of Federal Claims No: 20–0916V
71. James Kincaid, Washington, District of Columbia, Court of Federal Claims No: 20–0917V
72. Ashley Nore, Huntsville, Alabama, Court of Federal Claims No: 20–0919V
73. Tawana T. Morrison, Rochester, New York, Court of Federal Claims No: 20–0921V
74. Theresa Pistochini, Washington, District of Columbia, Court of Federal Claims No: 20–0922V
75. Eric Newak, Coer d'Alene, Idaho, Court of Federal Claims No: 20–0923V
76. Jodi Solem, Washington, District of Columbia, Court of Federal Claims No: 20–0925V
77. Jodi Solem, Washington, District of Columbia, Court of Federal Claims No: 20–0927V
78. Ayon Wen-Waldron on behalf of The Estate of Darryl Waldron, Washington, District of Columbia, Court of Federal Claims No: 20–0928V
79. Samantha Ivers, Elk Grove Village, Illinois, Court of Federal Claims No: 20–0929V
80. Amber Bob on behalf of G. B., Phoenix, Arizona, Court of Federal Claims No: 20–0931V
81. Ijeoma Chukwudum, Houston, Texas, Court of Federal Claims No: 20–0936V
82. Carl Carnes, Beverly Hills, California, Court of Federal Claims No: 20–0937V
83. Mary Ward, Fontana, California, Court of Federal Claims No: 20–0938V
84. Olivia Renchen, Beverly Hills, California, Court of Federal Claims No: 20–0939V
85. Darla Conley, Beverly Hills, California, Court of Federal Claims No: 20–0940V
86. Linda Howard, Dresher, Pennsylvania, Court of Federal Claims No: 20–0941V
87. Erin Mattheis, Beverly Hills, California, Court of Federal Claims No: 20–0942V
88. Lillie Johnson, Dresher, Pennsylvania, Court of Federal Claims No: 20–0943V
89. Theresa Cristoph, Richmond, Virginia, Court of Federal Claims No: 20–0945V
90. Jessica Mott on behalf of Lola Crawford, New York, New York, Court of Federal Claims No: 20–0947V
91. Annika Olsen-Santoro, Pasadena, California, Court of Federal Claims No: 20–0948V
92. Randy Moore, Washington, District of Columbia, Court of Federal Claims No: 20–0949V

[FR Doc. 2020–17936 Filed 8–14–20; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the Council of Councils, September 11, 2020, 08:15 a.m. to 04:00 p.m., National Institutes of Health, Natcher Building, Building 45 Room D, C1/C2 and G1/G2, 45 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on December 16, 2019, 84 FR 68467.

The meeting notice is amended to change the open and closed session meeting times as follows: The open session will now be held from 10:15 a.m. to 1:00 p.m. and from 2:15 p.m. to 4:55 p.m. with the closed session held from 1:00 p.m. to 2:00 p.m. This notice is also being amended to change the meeting location from National Institutes of Health, Natcher Building, Building 45 Room D, C1/C2 and G1/G2, 45 Center Drive, Bethesda, MD 20892 to a virtual meeting. The url link to this meeting can be found at: <http://videocast.nih.gov/>. Any member of the public may submit written comments no later than 15 days after the meeting.

Dated: August 12, 2020.

Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–17907 Filed 8–14–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Advisory Board.

The meeting will be held as a virtual meeting and is open to the public as

indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board.

Date: September 1, 2020.

Open: 1:00 p.m. to 5:45 p.m.

Agenda: NCAB Subcommittee Meetings—Subcommittee on Planning and Budget; *Ad Hoc* Subcommittee on Experimental Therapeutics; *Ad Hoc* Subcommittee on Population Science, Epidemiology and Disparities; and *Ad Hoc* Subcommittee on Global Cancer Research.

Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meetings).

Instructions regarding access to the virtual Subcommittee Meetings will be posted at: <https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>.

Name of Committee: National Cancer Advisory Board.

Date: September 2, 2020.

Open: 1:00 p.m. to 3:15 p.m.

Agenda: Director's and Program reports and presentations; business of the Board.

Closed: 3:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting).

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W444 Bethesda, MD 20892, 240–276–6340, grayp@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: NCAB: <https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>, where an agenda,

instructions for accessing the virtual NCAB meetings, and any additional information for the meetings will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 12, 2020.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–17906 Filed 8–14–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

A portion of this meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Drug Abuse.

Date: September 10, 2020.

Closed: 11:00 a.m. to 12:15 p.m.

Agenda: To review and evaluate grant applications.

Open: 12:45 p.m. to 4:30 p.m.

Agenda: Presentations and other business of the Council.

Place: National Institutes of Health, National Institute on Drug Abuse, Neurosciences Center Building, 6001

Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC 9591, Rockville, MD 20892, 301–443–6487, sweiss@nida.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: August 11, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–17817 Filed 8–14–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19).

Date: August 27, 2020.